Advertisement
Singapore markets closed
  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     
  • S&P 500

    5,000.79
    -70.84 (-1.40%)
     
  • Dow

    37,936.14
    -524.78 (-1.36%)
     
  • Nasdaq

    15,374.09
    -338.66 (-2.16%)
     
  • Bitcoin USD

    63,210.42
    -2,826.82 (-4.28%)
     
  • CMC Crypto 200

    1,339.82
    -42.76 (-3.09%)
     
  • FTSE 100

    8,049.77
    +9.39 (+0.12%)
     
  • Gold

    2,327.40
    -11.00 (-0.47%)
     
  • Crude Oil

    82.88
    +0.07 (+0.08%)
     
  • 10-Yr Bond

    4.7310
    +0.0790 (+1.70%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     
  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Endo International’s Specialty and Established Products in Q1

Endo International’s Specialty and Established Products in Q1

Endo International’s (ENDP) net interest expense increased from $111.9 million in Q1 2017 to $123.9 million in Q1 2018. While the company received an income tax benefit of $11.9 million in Q1 2017, it had an income tax expense of $15.49 million in Q1 2018. That led to an increase in its net loss from $173.83 million in Q1 2017 to $505.48 million in Q1 2018. That translated to a net loss per share of $2.26 in Q1 2018 compared to a net loss per share of $0.78 in Q1 2017.